Over the past two decades, research on body composition has expanded rapidly, revealing its critical role in clinical applications, particularly in oncology. Despite its potential to enhance patient stratification, treatment response assessment, and overall clinical outcomes, body composition analysis remains underutilized in oncology trials.

Developed in collaboration with Syneos Health, this white paper explores the barriers preventing its widespread adoption, including challenges related to clinical evidence, accessibility of assessment tools, usability, and cost-effectiveness. It also highlights the growing body of research supporting the integration of body composition analysis into clinical trials and outlines a compelling case for its implementation.

By addressing these challenges, we can unlock the full potential of this innovative biomarker, leading to more personalized and effective cancer treatments.

Download the full white paper to learn more about how body composition assessment can revolutionize oncology research.